OBJECTIVE: To probe into the effects of sakobactri valsartan on cardiac function

blood glucose control and prognosis in patients with chronic Heart Failure complicated with diabetes mellitus. METHODS: Totally 120 patients with chronic Heart Failure complicated with diabetes mellitus admitted into Qionghai Hospital of Traditional Chinese Medicine from Jan. 2017 to Jan. 2019 were extracted to be divided into the conventional group（ n = 60） and the study group（ n = 60） via the random number table. The conventional group was given the conventional treatment regimen

while the study group received sakobactril valsartan on the basis of the conventional treatment. Cardiac function indicators and blood glucose indicators of two groups were compared before treatment and after treatment of 12 months

and the occurrence of adverse drug reactions and major adverse cardiac events（ MACE）were observed. RESULTS: After treatment

the left ventricular ejection fraction

stroke volume and 6-min walk test of two groups were significantly higher than those before treatment

and the study group was significantly higher than the conventional group

the differences were statistically significant（ P<0. 05）. After treatment

the N-terminal pro-B-type natriuretic peptide

fasting blood glucose

2 h postprandial blood glucose and glycosylated hemoglobin levels of two groups were significantly lower than those before treatment

and the study group was significantly lower than the conventional group

the differences were statistically significant（ P<0. 05）. The incidence of adverse drug reactions in the conventional group and the study group was respectively 12. 28%（ 7/57） and 15. 52%（ 9/58）

with no statistically significant difference（ P = 0. 616）. The 12-month cumulative MACE events of the study group and the conventional group were respectively 18 cases and 29 cases

the risk of MACE in the study group was significantly lower than that of the conventional group

and the difference was statistically significant（ P<0. 05）. The proportion of smoking history

atrial fibrillation

history of myocardial infarction and hyperlipidemia in MACE group was significantly higher than that in non-MACE group

the proportion of patients taking sakobactril valsartan was significantly lower than that of non-MACE group

with statistically significant difference（ P < 0. 05）. Multivariate Cox regression analysis showed that atrial fibrillation

hyperlipidemia were independent risk factors for MACE in patients with chronic Heart Failure complicated with diabetes mellitus

and sakobactril valsartan was the protective factor for MACE in patients with chronic Heart Failure complicated with diabetes mellitus. CONCLUSIONS: Saurbactral valsartan can effectively improve the cardiac function

blood glucose levels and prognosis of patients with chronic Heart Failure complicated with diabetes mellitus.